Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer-Reference-Cited by-同舟云学术

Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer

Published:2017-01-31 Issue:14 Volume:23 Page:3676-3683
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Singer Christian F.,Tan Yen Y.,Fitzal Florian,Steger Guenther G.,Egle Daniel,Reiner Angelika,Rudas Margaretha,Moinfar Farid,Gruber Christine,Petru Edgar,Bartsch Rupert,Tendl Kristina A.,Fuchs David,Seifert Michael,Exner Ruth,Balic Marija,Bago-Horvath Zsuzsanna,Filipits Martin,Gnant Michael

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in China;World Journal of Surgical Oncology;2024-04-06

2. Clinical application of the HM-1000 image processing for HER2 fluorescence in situ hybridization signal quantification in breast cancer;Diagnostic Pathology;2024-02-15

3. Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer;Breast Cancer Research;2024-02-07

4. Predictive markers for pathological complete response (pCR) after neo-adjuvant chemotherapy in HER2-positive breast carcinoma;HISTOL HISTOPATHOL;2024

5. HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results;Breast Cancer Research;2023-12-14